^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    kt-3283

    i
    Other names: kt-3283
    Associations

    News

    Trials
    Company:
    Rakovina Therap
    Drug class:
    PARP inhibitor, HDAC inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma. (PubMed, Clin Cancer Res)
    Our data demonstrates the preclinical justification for studying the benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma in a clinical trial and provides proof-of-concept for a bi-functional single-molecule therapeutic strategy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    MET expression
    |
    Lynparza (olaparib) • Zolinza (vorinostat) • kt-3000 series • kt-3283